Eli Lilly Q3 revenue surges 39% to $24.4 billion as guidance rises

Full story: https://grafa.com/en/news/united-states/eli-lilly-q3-2026-revenue-rises-39-percent

Key points

Eli Lilly (NYSE:LLY) reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year, with adjusted EPS of $7.48.
Mounjaro revenue climbed 65% to $10.7 billion, while Zepbound revenue increased approximately 48%–49% to $5.3 billion–$5.4 billion.
Lilly raised its 2026 revenue outlook to $91 billion–$92 billion and set adjusted EPS guidance at $35–$36 per share.

Eli Lilly and Company (NYSE:LLY) reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year, beating analyst expectations as strong demand for its weight-loss and diabetes medicines supported growth.

Adjusted earnings per share reached $7.48, while GAAP net income increased to $6.45 billion from $5.58 billion a year earlier.

GAAP diluted EPS rose to $7.22 from $6.21.

Mounjaro revenue increased 65% to $10.7 billion, while Zepbound revenue grew approximately 48%–49% to between $5.3 billion and $5.4 billion.

Foundayo, Lilly's oral GLP-1 medicine, generated $184 million in its first full quarter, below analyst expectations of approximately $234 million.

Lilly raised its full-year 2026 revenue guidance to $91 billion–$92 billion.

Adjusted EPS guidance was set at $35–$36 per share, reflecting improved underlying performance offset by acquired in-process research and development charges from recent business development deals.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":623911791084312,"tweetId":"623911791084312","gmtCreate":1793337649163,"gmtModify":1793337656755,"author":{"id":4169784042383112,"idStr":"4169784042383112","authorId":4169784042383112,"authorIdStr":"4169784042383112","name":"Grafa","avatar":"https://community-static.tradeup.com/news/ec1614006170d0aa3182195a94e8944d","vip":2,"userType":2,"introduction":"Grafa generates AI-driven data, news and analysis about NYSE, Nasdaq and ASX stocks","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":259,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/f8951e9ef67b4c7367e02429aa6a0690","width":"1672","height":"941"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/f8951e9ef67b4c7367e02429aa6a0690","width":"1672","height":"941"}],"title":"Eli Lilly Q3 revenue surges 39% to $24.4 billion as guidance rises","html":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/f8951e9ef67b4c7367e02429aa6a0690\" tg-width=\"1672\" tg-height=\"941\"></p>\n<p>Full story: https://grafa.com/en/news/united-states/eli-lilly-q3-2026-revenue-rises-39-percent</p>\n<h2>Key points</h2>\n<ul>\n <li>\n  <p>Eli Lilly (NYSE:LLY) reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year, with adjusted EPS of $7.48.</p></li>\n <li>\n  <p>Mounjaro revenue climbed 65% to $10.7 billion, while Zepbound revenue increased approximately 48%–49% to $5.3 billion–$5.4 billion.</p></li>\n <li>\n  <p>Lilly raised its 2026 revenue outlook to $91 billion–$92 billion and set adjusted EPS guidance at $35–$36 per share.</p></li>\n</ul>\n<p>Eli Lilly and Company (NYSE:LLY) reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year, beating analyst expectations as strong demand for its weight-loss and diabetes medicines supported growth.</p>\n<p>Adjusted earnings per share reached $7.48, while GAAP net income increased to $6.45 billion from $5.58 billion a year earlier.</p>\n<p>GAAP diluted EPS rose to $7.22 from $6.21.</p>\n<p>Mounjaro revenue increased 65% to $10.7 billion, while Zepbound revenue grew approximately 48%–49% to between $5.3 billion and $5.4 billion.</p>\n<p>Foundayo, Lilly's oral GLP-1 medicine, generated $184 million in its first full quarter, below analyst expectations of approximately $234 million.</p>\n<p>Lilly raised its full-year 2026 revenue guidance to $91 billion–$92 billion.</p>\n<p>Adjusted EPS guidance was set at $35–$36 per share, reflecting improved underlying performance offset by acquired in-process research and development charges from recent business development deals.</p></body></html>","htmlText":"<html><head></head><body><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/f8951e9ef67b4c7367e02429aa6a0690\" tg-width=\"1672\" tg-height=\"941\"></p>\n<p>Full story: https://grafa.com/en/news/united-states/eli-lilly-q3-2026-revenue-rises-39-percent</p>\n<h2>Key points</h2>\n<ul>\n <li>\n  <p>Eli Lilly (NYSE:LLY) reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year, with adjusted EPS of $7.48.</p></li>\n <li>\n  <p>Mounjaro revenue climbed 65% to $10.7 billion, while Zepbound revenue increased approximately 48%–49% to $5.3 billion–$5.4 billion.</p></li>\n <li>\n  <p>Lilly raised its 2026 revenue outlook to $91 billion–$92 billion and set adjusted EPS guidance at $35–$36 per share.</p></li>\n</ul>\n<p>Eli Lilly and Company (NYSE:LLY) reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year, beating analyst expectations as strong demand for its weight-loss and diabetes medicines supported growth.</p>\n<p>Adjusted earnings per share reached $7.48, while GAAP net income increased to $6.45 billion from $5.58 billion a year earlier.</p>\n<p>GAAP diluted EPS rose to $7.22 from $6.21.</p>\n<p>Mounjaro revenue increased 65% to $10.7 billion, while Zepbound revenue grew approximately 48%–49% to between $5.3 billion and $5.4 billion.</p>\n<p>Foundayo, Lilly's oral GLP-1 medicine, generated $184 million in its first full quarter, below analyst expectations of approximately $234 million.</p>\n<p>Lilly raised its full-year 2026 revenue guidance to $91 billion–$92 billion.</p>\n<p>Adjusted EPS guidance was set at $35–$36 per share, reflecting improved underlying performance offset by acquired in-process research and development charges from recent business development deals.</p></body></html>","text":"Full story: https://grafa.com/en/news/united-states/eli-lilly-q3-2026-revenue-rises-39-percent Key points Eli Lilly (NYSE:LLY) reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year, with adjusted EPS of $7.48. Mounjaro revenue climbed 65% to $10.7 billion, while Zepbound revenue increased approximately 48%–49% to $5.3 billion–$5.4 billion. Lilly raised its 2026 revenue outlook to $91 billion–$92 billion and set adjusted EPS guidance at $35–$36 per share. Eli Lilly and Company (NYSE:LLY) reported third-quarter 2026 revenue of $24.4 billion, up 39% year over year, beating analyst expectations as strong demand for its weight-loss and diabetes medicines supported growth. Adjusted earnings per share reached $7.48, while GAAP net income increased to $6.45 billion from $5.58 billion a year earlier. GAAP diluted EPS rose to $7.22 from $6.21. Mounjaro revenue increased 65% to $10.7 billion, while Zepbound revenue grew approximately 48%–49% to between $5.3 billion and $5.4 billion. Foundayo, Lilly's oral GLP-1 medicine, generated $184 million in its first full quarter, below analyst expectations of approximately $234 million. Lilly raised its full-year 2026 revenue guidance to $91 billion–$92 billion. Adjusted EPS guidance was set at $35–$36 per share, reflecting improved underlying performance offset by acquired in-process research and development charges from recent business development deals.","highlighted":1,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/623911791084312","repostId":0,"isVote":1,"tweetType":1,"viewCount":3,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1234,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/623911791084312"}